Dianthus Therapeutics, Inc.
- Last sale
- Nov 12, 2026 · +3.74%
- Market cap
- $5.21B
- 56.31M shares
- Filings
- 661
FY 2025−67.3% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q2 2023derivedN/M FY22 yoy
Q3 2026N/M FY25 yoy
Q3 2026+124.1% FY25 yoy
- $5.21B
- —
- 2559.2×
- 4.2×
- —
- —
FY2025 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $2,036,000 | reported | |
| FY 2024 | 2024-12-31 | $6,235,000 | reported | |
| FY 2023 | 2023-12-31 | $2,826,000 | reported | |
| FY 2019 | 2019-12-31 | $0 | reported | |
| FY 2018 | 2018-12-31 | $0 | reported | |
| FY 2017 | 2017-12-31 | $0 | reported | |
| FY 2016 | 2016-12-31 | $0 | reported |
Pharmaceutical preparations
Dianthus Therapeutics, Inc. is the 201st largest of the 552 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
RNACCartesian Therapeutics, Inc.$2.8M92.8%4,658.6%$194.3MTRAWTraws Pharma, Inc.$2.8M1,134.5%328.7%$4.2MGOVXGeoVax Labs, Inc.$2.5M37.1%862.3%$1.1MKRSAKorsana Biosciences, Inc.$2.1M3.7%170.1%$1.4B
DNTHDianthus Therapeutics, Inc. (this company)$2.0M67.3%7,973.3%$5.2B
ORMPOramed Pharmaceuticals Inc.$2.0M—3,202.5%$175.2MLPCNLipocine Inc.$2.0M82.3%487.1%$17.9MBIOEBio Essence Corp$1.9M485.8%47.2%$19.0MRANIRani Therapeutics Holdings, Inc.$1.6M58.9%1,817.1%$75.6MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Dianthus Therapeutics, Inc. · CIK 1690585 · Engraved from SEC EDGAR